IGM-001

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIGM-001

Drug Alias NameCTLA4-IgG2 soluble fusion protein (IgeniMed)IGM-001

ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCluster of differentiation 80 inhibitorsCluster of differentiation 86 inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 stimulants

TargetsCluster of differentiation 80Cytotoxic T-Lymphocyte-Associated Antigen 4Cluster of differentiation 86

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesIgeniMed Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgeniMed Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A